Category Specific RSS

pxs

First patients dosed in Phase 2 clinical trials to tackle Parkinson’s disease

Parkinson’s UK, in collaboration with Australian researchers, has taken a major step towards preventing the development of Parkinson’s disease with…

2 years ago

Pharmaxis accelerates clinical drug developments with additional resources via sale of mannitol business to Arna Pharma

With a burgeoning pipeline of drugs deeply advanced, clinical stage biopharmaceuticals company Pharmaxis (ASX: PXS) has streamlined its business with…

2 years ago

Encouraged by interim data, FDA approves Pharmaxis to expand its myelofibrosis treatment trials

Fresh off reporting final interim data from their Phase 2 clinical trials for PXS-5505 to treat myelofibrosis, biotech company Pharmaxis…

2 years ago

Pharmaxis delivers impressive Phase 2 clinical data to treat myelofibrosis, pushing on to FDA discussions

In a potential breakthrough for the field of bone marrow cancer treatment, biotech company Pharmaxis (ASX: PXS) has released the…

2 years ago

German researchers publish ‘best ever’ results for urgently needed blood cancer treatment

There is an urgent need for better treatment for myelodysplastic syndrome (MDS), a type of blood cancer, and new research…

3 years ago